Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.52 |
| ▸ | TUBB | P07437 | 2/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL3134333 | 0.96 | NR1H4 (0.57) | NR1H4ALOX5ALDH1A1MAPTCYP2C9 | |
| SCHEMBL3135730 | 0.85 | MAPT (0.46) | NR1H4ALOX5ALDH1A1MAPTCYP2C9 | |
| SCHEMBL3127815 | 0.82 | ALDH1A1 (0.48) | NR1H4ALDH1A1MAPTCYP2C9TUBB4A | |
| SCHEMBL3133245 | 0.82 | TUBB4A (0.48) | NR1H4ALOX5ALDH1A1MAPTCYP2C9 | |
| SCHEMBL3141244 | 0.81 | NR1H4 (0.47) | NR1H4ALDH1A1MAPTCYP2C9TUBB4A | |
| SCHEMBL10470600 | 0.79 | ALOX5 (0.71) | NR1H4ALOX5ALDH1A1MAPTSHMT2 | |
| SCHEMBL432850 | 0.79 | ALOX5 (0.71) | NR1H4ALOX5ALDH1A1MAPTSHMT2 | |
| SCHEMBL3127787 | 0.79 | NR1H4 (0.51) | NR1H4ALDH1A1MAPTCYP2C9TUBB4A | |
| SCHEMBL3136921 | 0.78 | NR1H4 (0.55) | NR1H4ALDH1A1MAPTCYP2C9TUBB4A | |
| SCHEMBL14013663 | 0.77 | SHMT2 (0.41) | NR1H4ALOX5ALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751128-B1 | CHROMENE-DERIVATIVES WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY | OXIGENE INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1751128-B1 | CHROMENE-DERIVATIVES WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY | OXIGENE INC (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7456214-B2 | Cancer; for selectively destroying tumor vasculature; inhibit tubulin polymerization; selectively reducing blood flow to at least a portion of a neoplastic region; 3-(3',4',5'-Trimethoxybenzoyl)-6-hydroxy-7-methoxy-2H-chromene | BAYLOR UNIVERSITY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456214-B2 | Cancer; for selectively destroying tumor vasculature; inhibit tubulin polymerization; selectively reducing blood flow to at least a portion of a neoplastic region; 3-(3',4',5'-Trimethoxybenzoyl)-6-hydroxy-7-methoxy-2H-chromene | BAYLOR UNIVERSITY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456214-B2 | Cancer; for selectively destroying tumor vasculature; inhibit tubulin polymerization; selectively reducing blood flow to at least a portion of a neoplastic region; 3-(3',4',5'-Trimethoxybenzoyl)-6-hydroxy-7-methoxy-2H-chromene | BAYLOR UNIVERSITY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1751128-A1 | CHROMENE-DERIVATIVES WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY | OXIGENE, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113532-A1 | CHROMENE-DERIVATIVES WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY | OXIGENE, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050245490-A1 | Chromene-containing compounds with anti-tubulin and vascular targeting activity | MATEON THERAPEUTICS, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245490-A1 | Chromene-containing compounds with anti-tubulin and vascular targeting activity | TUBB1, TUBB3, TUBB | NR1H4 1169/4885ALOX5 4269/4885ALDH1A1 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.